Form 4: Tenaya Therapeutics CEO Sells Shares

Sentiment:

Insider Transaction (Form 4)


Faraz Ali, Chief Executive Officer and a Director of Tenaya Therapeutics, Inc., sold 22,232 shares of common stock on August 17, 2026.

Summary

  • Open-market sale: disposed of 5,837 Common Stock at $0.71 ($4,143) on August 17, 2026; holds 434,177 after (Direct).
  • Open-market sale: disposed of 3,969 Common Stock at $0.71 ($2,817) on August 17, 2026; holds 430,208 after (Direct).
  • Open-market sale: disposed of 5,020 Common Stock at $0.71 ($3,563) on August 17, 2026; holds 425,188 after (Direct).
  • Open-market sale: disposed of 7,406 Common Stock at $0.71 ($5,256) on August 17, 2026; holds 417,782 after (Direct).

Sentiment

Score: 4

Explanation: StockSavvy.ai views this as a mildly negative signal: an insider sold $15,778 of stock on the open market.

Insider Transactions

Faraz Ali — Director, Officer (Chief Executive Officer)

DateTransactionSecuritySharesPriceValueHeld After
2026-08-17Open-market saleCommon Stock5,837$1$4.1K434,177
2026-08-17Open-market saleCommon Stock3,969$1$2.8K430,208
2026-08-17Open-market saleCommon Stock5,020$1$3.6K425,188
2026-08-17Open-market saleCommon Stock7,406$1$5.3K417,782

Key Dates

DateDescription
2026-08-17Open-market sale (5,837 shares)
2026-08-17Open-market sale (3,969 shares)
2026-08-17Open-market sale (5,020 shares)
2026-08-17Open-market sale (7,406 shares)

Keywords

insider transaction, Form 4, TNYA, Tenaya Therapeutics, Inc., bearish, Faraz Ali

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.